Cost Development

Analyze costs, margins, and profitability across products and customers

Gross Margin

34.2%

+1.2% vs LY

Net Margin

18.7%

-0.8% vs LY

Rebate Liability

$12.4M

Current period

Avg Cost-to-Serve

$4.23

-$0.15 vs LQ

Below Threshold

Products < 15% margin

Margin at Risk

$2.1M

From cost increases

Margin Performance Trend

Jul

Aug

Sep

Oct

Nov

Gross Margin

Net Margin

Target (20%)

Cost Composition

$84.5M

Total Costs

Product Cost (COGS)

50%

Distribution

20%

Rebates

15%

Handling

10%

Other

Margin by Segment

Hospital - Acute Care 24.5%

Pharmacy - Retail 21.2%

Distributor 17.8%

Long Term Care 15.3%

Mail Order Pharmacy 12.1%

Above Target (>20%) At Risk (15-20%) Below Target (<15%)

View detailed analysis

Cost Alerts

View All

Negative margin on 5 products

Oncology category - requires immediate review

Critical

COGS increase: Pfizer products

8.5% average increase effective Jan 1

High

Rebate liability exceeding budget

$1.2M over Q4 budget forecast

High

Distribution cost variance

West region 12% above average

Medium

Quick Access

Product Costs

Analyze by NDC

Margin Analysis

Multi-dimensional

Cost-to-Serve

Customer profitability

Rebate Impact

Margin erosion

Scenario Modeling

What-if analysis

Reports

Standard & custom